Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02620176
Other study ID # Farmer-2
Secondary ID
Status Recruiting
Phase N/A
First received December 15, 2014
Last updated November 28, 2015
Start date December 2014
Est. completion date February 2016

Study information

Verified date November 2015
Source Wingate Institute of Neurogastroenterology
Contact Adam D Farmer, PhD MRCP
Phone 02088822640
Email a.farmer@qmul.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We are evaluating the role of transcutaneous electrical vagal nerve stimulation in the prevention of oesophageal pain hypersensitivity using a validated human model in healthy volunteers.


Description:

Chronic oesophageal pain is a symptomatic feature of disorders such as erosive oesophagitis, non-erosive reflux disease and non-cardiac chest pain. Patients often display heightened sensitivity to intra-oesophageal stimuli, which is referred to as oesophageal pain hypersensitivity. However, the experience of oesophageal pain is highly individual with a multitude of factors proposed to account for this variability. Amongst the physiological factors is the autonomic nervous system (ANS). The ANS has been postulated to play a pivotal role in the modulation of pain through its multiple interactions with pain processing. The ANS has two broadly antithetic branches, the parasympathetic nervous system (PNS) and the sympathetic nervous system (SNS). The primary neural substrate of the PNS is the vagus nerve. The vagus nerve is increasingly considered to play an integral role in modulating oesophageal pain. Electrical vagal nerve stimulation (VNS) was first used in humans in 1988 and is an efficacious treatment for drug resistant epilepsy. Traditional VNS is undertaken in a procedure where a bipolar helical electrode is placed around the cervical vagal nerve, which is connected to a pulse generator placed in subcutaneous pocket in the chest, not dissimilar to a cardiac pacemaker. However, this method of VNS necessitates surgical implantation with its attendant risks and complications. Recently, an external transcutaneous VNS (t-VNS) system, consisting of an earplug-like electrode to interface with the concha of the outer ear and a handheld battery-powered electrical stimulator, has become commercially available (NEMOS system). The auricular branch of the vagus nerve innervates the concha of the ear and is located directly under the skin, making it a suitable target for transcutaneous stimulation. t-VNS has been demonstrated to be safe, well tolerated and have a high degree of user-friendliness. A preliminary study has reported that t-VNS reduces sensitivity to heat pain in healthy volunteers. Furthermore, recent studies have demonstrated that t-VNS patterns of cerebral activation, as determined by functional magnetic resonance imaging, were similar to those evoked by traditional VNS. Thus, VNS per se represents an attractive proposition for investigating the role of the PNS in oesophageal pain and t-VNS specifically, a viable, safe and acceptable technology for achieving this. The pivotal experiments evaluating the analgesic role of VNS in the development of acid induced oesophageal pain hypersensitivity have not been conducted. Using the aforementioned model of oesophageal pain hypersensitivity, we seek to determine the analgesic effect of t-VNS.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Ability to provide Informed written consent

- Healthy volunteers aged 18-65, who have no medical history

Exclusion Criteria:

- Any inclusion criteria not met

- Subjects unable to provide informed consent.

- Subjects with any systemic disease or medications that may influence the autonomic nervous system (e.g. beta-agonists or Parkinson's disease).

- Pregnant females to prevent any confounding effects on pregnancy related nausea.

- Subjects who suffer from reflux disease

- Subject who take any medication, including over the counter preparations

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcutaneous vagal nerve stimulation
Trans-auricular vagal nerve stimulation

Locations

Country Name City State
United Kingdom Wingate Institute of Neurogastroenterology London

Sponsors (1)

Lead Sponsor Collaborator
Wingate Institute of Neurogastroenterology

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Botha C, Farmer AD, Nilsson M, Brock C, Gavrila AD, Drewes AM, Knowles CH, Aziz Q. Preliminary report: modulation of parasympathetic nervous system tone influences oesophageal pain hypersensitivity. Gut. 2015 Apr;64(4):611-7. doi: 10.1136/gutjnl-2013-306698. Epub 2014 May 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met. 90 minutes post acid infusion
Secondary Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met. 30 minutes post acid infusion
Secondary Sensitisation to electrical stimuli in the proximal oesophagus following a distal oesophageal acid infusion in comparison to baseline Pain tolerance thresholds to electrical stimulation in the proximal oesophagus decrease following a distal oesophageal acid infusion due to central sensitisation and are defined as a reduction of >6mA in thresholds. Prevention of sensitisation will be defined as this threshold not being met. 60 minutes post acid infusion
Secondary Effect of vagal nerve stimulation on cardiac vagal tone during stimulation in comparison to baseline The effect of vagal stimulation on the validated parameter of cardiac vagal tone 30 minutes
Secondary Effect of vagal nerve stimulation on cardiac sympathetic index during stimulation in comparison to baseline The effect of vagal stimulation on the validated parameter of cardiac sympathetic index. 30 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT05054933 - Ultrasound Capsule Endoscopy for Esophagus Examination N/A
Completed NCT04090554 - Cytospongeâ„¢ Feasibility Study in Tanzania N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Recruiting NCT04481100 - CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer Phase 2
Completed NCT03859557 - The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Completed NCT00977678 - Drop in Gastroscopy - Experience After 9 Months N/A
Recruiting NCT04068480 - Esophageal and Gastric Diseases With Robotically Controlled Magnetic Capsule Endoscopy
Completed NCT00874263 - Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies N/A
Terminated NCT00442507 - Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction Phase 2
Recruiting NCT03832959 - Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study. N/A
Withdrawn NCT02569073 - Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain Phase 4
Recruiting NCT05252078 - Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients Phase 2
Recruiting NCT00260585 - Esophageal Cancer Risk Registry
Completed NCT03187314 - Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer Phase 2
Recruiting NCT05004155 - Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
Recruiting NCT05469152 - Detachable String Magnetically Controlled Capsule Endoscopy for Follow-up of Patients With Esophageal Diseases N/A
Recruiting NCT05877300 - Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement Phase 1
Recruiting NCT03267355 - Indications and Outcomes of Endoscopic Ultrasound in Tanta N/A
Recruiting NCT00939263 - Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index N/A